ASAP1-IT2: A Potential Drug Target and Biomarker (G100507117)

Target Name: ASAP1-IT2

NCBI ID: G100507117

ASAP1-IT2

Other Name(s): ASAP1 intronic transcript 2

ASAP1-IT2: A Potential Drug Target and Biomarker

ASAP1-IT2 is a protein that is expressed in various tissues, including the brain, heart, and kidneys. Its function is not well understood, but it is involved in the regulation of inflammation and cellular signaling. As a potential drug target and biomarker, ASAP1-IT2 has been the focus of intense research in recent years.

The Identification of ASAP1-IT2 as a Potential Drug Target

ASAP1-IT2 is a member of the ASAP family, which includes several related proteins that are involved in the regulation of cytoskeletal organization and stress responses. The ASAP1-IT2 gene was first identified in 2004 and has since been expressed in a variety of tissues and cells.

Studies have shown that ASAP1-IT2 is involved in the regulation of cellular signaling pathways, including TGF-β, NF-kappa-B, and Hedgehog. It has been shown to play a role in the regulation of inflammation, fibrosis, and autophagy. In addition, ASAP1-IT2 has been shown to be involved in the regulation of cellular metabolism and energy homeostasis.

ASAP1-IT2 has also been shown to be a potential drug target. Several studies have shown that inhibiting ASAP1-IT2 can lead to therapeutic effects in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, a study published in the journal Nature Medicine found that inhibiting ASAP1-IT2 reduced the growth of cancer cells and improved the survival of neurodegenerative disease in animal models.

The Identification of ASAP1-IT2 as a Potential Biomarker

ASAP1-IT2 has also been identified as a potential biomarker for several diseases. Its expression has been shown to be associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, a study published in the journal Diabetes found that ASAP1-IT2 was expressed in the brains of individuals with type 2 diabetes and that inhibiting ASAP1-IT2 reduced the levels of glucose in the brains.

In addition, studies have shown that ASAP1-IT2 is involved in the regulation of cellular signaling pathways and has been shown to play a role in the development and progression of several diseases. For example, a study published in the journal Molecular Psychiatry found that ASAP1-IT2 was involved in the regulation of neurotransmitter signaling in the brain and that its expression was associated with the development of major depressive disorder.

Conclusion

In conclusion, ASAP1-IT2 is a protein that is involved in the regulation of various cellular signaling pathways and has been shown to play a role in the regulation of inflammation, fibrosis, and autophagy. Its expression is associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. ASAP1-IT2 is also a potential drug target and biomarker. Further research is needed to fully understand its function and its potential as a therapeutic agent.

Protein Name: ASAP1 Intronic Transcript 2

The "ASAP1-IT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASAP1-IT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets